TIF was awarded for its notable contribution to advancing scientific knowledge in Haematology through its publication, “2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-Dependent Thalassaemia.”
The HemaSphere Awards were presented by the official journal of the European Hematology Association (EHA) during Europe’s most important scientific event in the field of Haematology, EHA2024 Hybrid Congress, held this year in Madrid, Spain, from 13 to 16 June 2024. Among thousands of submissions, the TIF paper was recognised for its popularity and impact among scientists, physicians, and researchers worldwide.
Mr. Loris Brunetta, a TIF Board Member, Thalassaemia Patient Expert, and Special Representative of the Federation on European Affairs, accepted the award on behalf of TIF. The ceremony was also attended by the eminent authors of the paper, Professors of Haematology Ali Taher, Maria D. Cappellini, John Porter and Dimitrios Farmakis.
Dr. Androulla Eleftheriou, TIF’s Executive Director, remarked on the occasion: “We are particularly proud to receive this prestigious award. It underscores the international scientific community’s recognition of our Guidelines’ value and their impact on improving health outcomes for thalassaemia patients worldwide. This acclaim also celebrates our ongoing efforts to develop educational tools aimed at enhancing clinical practices for those managing the disease.”
Expressing his gratitude, TIF’s President Mr. Panos Englezos stated: “We are delighted to receive this honour and extend our thanks to both the European Society of Haematology and our scientific partners—the authors—whose collaboration made this invaluable Guide possible. Amid rapid advancements in haematology and haemoglobinopathies, we bear an even greater responsibility to expedite our collaborative initiatives in delivering medical innovations’ benefits to individuals with haemoglobinopathies.”
Since their initial release in 1999 to present-day editions, the TIF Guidelines have been widely adopted by academics, researchers, and healthcare professionals globally as a definitive evidence-based reference for treating transfusion-dependent thalassaemia patients.
In addition, the Federation has published and distributes specific Guidelines for the management of both a-Thalassaemia and Non-Transfusion-Dependent Thalassaemia (NTDT).
